XyloCor Therapeutics is focused on improving the lives of people with cardiovascular disease through our commitment to advancing the science of gene therapy.
XyloCor Therapeutics Presents Phase 2 Data Highlighting Safety and Efficacy of XC001 at the European Society of Gene and Cell Therapy Meeting
More >>
XyloCor’s proprietary products address significant unmet clinical needs in cardiovascular disease.
More >>
XyloCor’s products are enabled by proprietary gene therapy technologies from Weill Cornell Medical College.
More >>